Anti-KMT2D monoclonal antibody

Pre-made anti-KMT2D monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to KMT2D/KMT2D products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2567-Ab-1/ GM-Tg-hg-IP2567-Ab-2Anti-Human KMT2D monoclonal antibodyHuman
GM-Tg-rg-IP2567-Ab-1/ GM-Tg-rg-IP2567-Ab-2Anti-Rat KMT2D monoclonal antibodyRat
GM-Tg-mg-IP2567-Ab-1/ GM-Tg-mg-IP2567-Ab-2Anti-Mouse KMT2D monoclonal antibodyMouse
GM-Tg-cynog-IP2567-Ab-1/ GM-Tg-cynog-IP2567-Ab-2Anti-Cynomolgus/ Rhesus macaque KMT2D monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2567-Ab-1/ GM-Tg-felg-IP2567-Ab-2Anti-Feline KMT2D monoclonal antibodyFeline
GM-Tg-cang-IP2567-Ab-1/ GM-Tg-cang-IP2567-Ab-2Anti-Canine KMT2D monoclonal antibodyCanine
GM-Tg-bovg-IP2567-Ab-1/ GM-Tg-bovg-IP2567-Ab-2Anti-Bovine KMT2D monoclonal antibodyBovine
GM-Tg-equg-IP2567-Ab-1/ GM-Tg-equg-IP2567-Ab-2Anti-Equine KMT2D monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2567-Ab-1/ GM-Tg-hg-IP2567-Ab-2; GM-Tg-rg-IP2567-Ab-1/ GM-Tg-rg-IP2567-Ab-2;
GM-Tg-mg-IP2567-Ab-1/ GM-Tg-mg-IP2567-Ab-2; GM-Tg-cynog-IP2567-Ab-1/ GM-Tg-cynog-IP2567-Ab-2;
GM-Tg-felg-IP2567-Ab-1/ GM-Tg-felg-IP2567-Ab-2; GM-Tg-cang-IP2567-Ab-1/ GM-Tg-cang-IP2567-Ab-2;
GM-Tg-bovg-IP2567-Ab-1/ GM-Tg-bovg-IP2567-Ab-2; GM-Tg-equg-IP2567-Ab-1/ GM-Tg-equg-IP2567-Ab-2
Products NameAnti-KMT2D monoclonal antibody
Formatmab
Target NameKMT2D
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-KMT2D monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2567-Ag-1Recombinant multi-species KMT2D/ AAD10/ ALR protein


    Target information

    Target IDGM-IP2567
    Target NameKMT2D
    Gene ID8085,381022,100362634,710795,486558,101095268,506805,100058932
    Gene Symbol and SynonymsAAD10,ALR,BCAHH,C430014K11Rik,CAGL114,KABUK1,KMS,KMT2B,KMT2D,MLL2,MLL4,TNRC21
    Uniprot AccessionO14686
    Uniprot Entry NameKMT2D_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseCancer
    Gene EnsemblENSG00000167548
    Target ClassificationTumor-associated antigen (TAA)

    The target: KMT2D, gene name: KMT2D, also named as AAD10, ALR, CAGL114, KABUK1, KMS, MLL2, MLL4, TNRC21. The protein encoded by this gene is a histone methyltransferase that methylates the Lys-4 position of histone H3. The encoded protein is part of a large protein complex called ASCOM, which has been shown to be a transcriptional regulator of the beta-globin and estrogen receptor genes. Mutations in this gene have been shown to be a cause of Kabuki syndrome. [provided by RefSeq, Oct 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.